Descriptive data including autoantibodies of study participants at baseline
| Parameter | Subjects (n=6) |
| Male (%) | 100 |
| Age (years) | 24.8±1.5 |
| Age at onset (years) | 10.3±2.2 |
| T1D duration (years) | 14.7±2.2 |
| BMI (kg/m2, ref: 20–25) | 22.6±1.4 |
| Hemoglobin (g/L, ref: 130–170) | 142.8±3.1 |
| Creatinine (µmol/L, ref: 60–105) | 74.2±2.2 |
| Bilirubin (µmol/L, ref: 5–25) | 14.4±2.0 |
| ALT (µkat/L, ref: 0.15–1.1) | 0.37±0.08 |
| AST (µkat/L, ref: 0.25–0.75) | 0.43±0.09 |
| ALP (µkat/L, ref: 0.6–1.8) | 1.4±0.1 |
| HbA1c (mmol/mol, ref: 27–42) | 64.8±6.2 |
| Fasting C peptide >0.01 nmol/L (n) | 1 |
| GAD positive (n) | 3 |
| IA2 positive (n) | 4 |
Reference values are presented within brackets.
The cut-off for positive GAD autoantibodies was set to >5 IE/mL and for IA2 to >7.5 kE/L according to clinical routine.
ALP, alkaline phosphate; ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; GAD, glutamic acid decarboxylase; HbA1c, hemoglobin A1c; IA2, Islet Antigen 2; ref, reference; T1D, type 1 diabetes.